FDA: Elevated Risk of Blood Clots in Lungs, Death in RA Patients on Higher Dose Tofacitinib
February 27th 2019A 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR, Pfizer) used in patients with rheumatoid arthritis increased the risk of blood clots in the lungs and death in a safety clinical trial.
Read More
FDA Approves New Treatment for Gastric, Gastroesophageal Junction Adenocarcinoma
February 26th 2019The FDA approved trifluridine/tipiracil (Lonsurf, Taiho Oncology), also known as TAS-102, as a treatment for certain adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
Read More
FDA Approves TAS-102 for Treating Adults With Gastric/GEJ Cancer
February 25th 2019The drug is indicated for those patients who were previously treated with at least 2 prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.
Read More
Detection of Impurity Prompts Company to Recall 1 Lot of Combination Tablets
February 23rd 2019Macleods Pharmaceuticals Limited has voluntarily recalled 1 lot of Losartan Potassium/Hydrochlorothiazide combination tablets 100mg/25mg to the consumer level, due to the detection of trace amounts of an unexpected impurity found in the product that is above the acceptable daily intake levels released by the FDA.
Read More